A PHASE II STUDY OF S-1 IN PATIENTS (PTS) WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)

被引：0
|
作者：
Naito, S. [1 ]
Akaza, H. [2 ]
Usami, M. [3 ]
Tsukamoto, T. [4 ]
Shinohara, N. [5 ]
Tomita, Y. [6 ]
Namiki, M. [7 ]
机构：
[1] Kyushu Univ Hosp, Fukuoka 812, Japan
[2] Tsukuba Univ Hosp, Tsukuba, Ibaraki, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[4] Sapporo Med Univ, Sapporo, Hokkaido, Japan
[5] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[6] Yamagata Univ, Sch Med, Yamagata 99023, Japan
[7] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [31] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [32] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).
    Amato, R. J.
    Misellati, A.
    Khan, M.
    Chiang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [33] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    CANCER INVESTIGATION, 2007, 25 : 20 - 21
  • [34] A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma
    Sakai, Hideki
    Ohba, Kojiro
    Hashine, Katsuyoshi
    Tomita, Yoshihiko
    Shinohara, Nobuo
    Fujisawa, Masato
    Eto, Masatoshi
    Ozono, Seiichiro
    Tsukamoto, Taiji
    Akaza, Hideyuki
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [35] Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
    Zang, D. Y.
    Lee, B. H.
    Park, H. -C.
    Song, H. H.
    Kim, H. J.
    Jung, J. Y.
    Kim, J. H.
    Kim, H. Y.
    Kwon, J. H.
    Hwang, S. W.
    Park, S. R.
    Park, C. H.
    Kim, K. O.
    Kim, M. -J.
    Jang, K. M.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 892 - 896
  • [36] Multicenter phase II trial of S-1 in patients (PTS) with hormone-refractory prostate cancer (HRPC): The S-1 cooperative study group (prostate cancer)
    Akaza, Hideyuki
    Ikemoto, Isao
    Namiki, Mikio
    Usami, Michiyuki
    Kobayashi, Mikio
    Fujimoto, Hiroyuki
    Tsukamoto, Taiji
    Naito, Seiji
    ANNALS OF ONCOLOGY, 2006, 17 : 150 - 150
  • [37] A phase II study of S-1 in patients with metastatic pancreatic cancer.
    Furuse, J
    Okusaka, T
    Funakoshi, A
    Boku, N
    Yamao, K
    Ohkawa, S
    Saito, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 333S - 333S
  • [38] Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
    Eto, Masatoshi
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Kanayama, Hiroomi
    Shinohara, Nobuo
    Kamei, Yoichi
    Fujii, Yosuke
    Umeyama, Yoshiko
    Ozono, Seiichiro
    Naito, Seiji
    Akaza, Hideyuki
    CANCER SCIENCE, 2014, 105 (12) : 1576 - 1583
  • [39] An early phase II study of S-1 in patients with metastatic pancreatic cancer
    Ueno, H
    Okusaka, T
    Ikeda, M
    Takezako, Y
    Morizane, C
    ONCOLOGY, 2005, 68 (2-3) : 171 - 178
  • [40] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
12345